• 1
    Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792800.
  • 2
    Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al, and The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25: 224378.
  • 3
    Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 98993.
  • 4
    Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 34450.
  • 5
    McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, et al, and the American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl ): 78S92S.
  • 6
    Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66: 146772.
  • 7
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 42534.
  • 8
    Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al, and the Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 8004.
  • 9
    Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al, and the Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496502.
  • 10
    Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al, and the Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. [published erratum appears in J Am Coll Cardiol 2003;42:591] J Am Coll Cardiol 2003; 41: 211925.
  • 11
    Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al, and the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 3229.
  • 12
    Channick R, Badesch DB, Tapson VF, Simmonneau G, Robbins I, Frost A, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. Lancet 2001; 358: 111923.
  • 13
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2002;346:1258]. N Engl J Med 2002; 346: 896903.
  • 14
    Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al, and the STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 4417.
  • 15
    Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al, and the STRIDE-1 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 204956.
  • 16
    Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al, and the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. [published erratum appears in N Engl J Med 2006;354:2400–1] N Engl J Med 2005; 353: 214857.
  • 17
    Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43 (12 Suppl S ): 48S55S.
  • 18
    Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 81S8S.
  • 19
    Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE, and OMERACT 6. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 163047.
  • 20
    Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25: 1989.
  • 21
    Bellamy N. Clinimetric concepts in outcome assessment: the OMERACT filter. J Rheumatol 1999; 26: 94850.
  • 22
    Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford) 2006; 45: 14557.
  • 23
    LinstoneH, TuroffM, editors. The Delphi method: techniques and applications. Newark (NJ): New Jersey Institute of Technology; 2002.
  • 24
    Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 37680.
  • 25
    Roth RM, Wood WC. A Delphi approach to acquiring knowledge from single and multiple experts. In: Awad EM, editor. Trends and direction in expert systems: proceedings of the 1990 ACM SIGBDP conference on trends and directions in expert systems. Orlando (FL): Association for Computing Machinery; 1990. p. 30124.
  • 26
    Young B, Linstone HA. Delphi method. In: OlsenSA, editor. Group planning and problem-solving: methods in engineering management. New York: John Wiley & Sons; 1982. p. 10354.
  • 27
    Deshpande AM, Shiffman RN, Nadkarni PM. Metadata-driven Delphi rating on the Internet. Comput Methods Programs Biomed 2005; 77: 4956.
  • 28
    Everitt BS. Cluster analysis. 3rd ed. London: Arnold; 1993.
  • 29
    Milligan G. An examination of the effect of six types of error perturbation on fifteen clustering algorithms. Psychometrika 1980; 45: 32542.
  • 30
    Peacock A, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004; 23: 94753.
  • 31
    Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials in systemic sclerosis. Ann Rheum Dis 2007. E-pub ahead of print.
  • 32
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 44252.
  • 33
    Taylor WJ. Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods. Ann Rheum Dis 2005; 64 Suppl 2: ii1102.